Alnylam Pharmaceuticals, Inc. is a pioneering pharmaceutical company based in the United States. Specializing in RNA interference (RNAi) therapeutics, Alnylam has developed and marketed several drugs targeting critical health conditions. With an ESG score of 27.3, the company is considered to have a medium risk level. Alnylam's portfolio includes drugs such as Onpattro, Amvuttra, Givlaari, Oxlumo, and Leqvio, addressing various genetic and metabolic disorders. The company's research partnerships have not only fueled its financial growth but also enabled it to advance clinical programs in different therapeutic areas.